CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 59 enrolled
Drug / intervention
Tamoxifendrug
Likely dose
Tamoxifen 20 mg orally once dailyAI-extracted
Key inclusion· 7
  • ✓Age ≥18 years
  • ✓Core biopsy-proven invasive carcinoma
  • ✓ER-alpha receptor positive tumor
  • ✓Tumor ≥1 cm on imaging or physical exam
Key exclusion· 12
  • ✕Male patients
  • ✕Inoperable tumor or stage 4 disease
  • ✕Diagnosis by FNA cytology only (not core biopsy)
  • ✕Pregnant or lactating

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01027416
NCT01027416N/ACompleted
CompareCT.gov

Pilot Study to Analyze a Novel Mechanism Underlying Response to Tamoxifen Therapy in Breast Cancer Patients

Roswell Park Cancer Institute·interventional·Posted Dec 8, 2009·Updated Apr 21, 2026

In Brief

A clinical study evaluating Tamoxifen for Breast Cancer. Completed, enrolled 59 participants across 2 sites.

Detailed Summary

This study will help to understand the interaction between estrogen receptor-alpha (ER alpha) and tumor suppressor protein p53 as well as impact on patient tumor gene expression in response to the hormonal therapy Tamoxifen. This information may eventually help select the appropriate therapy for future patients with similar cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH), National Cancer Institute (NCI)

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedDec 8, 2009
Enrollment StartDec 14, 2009
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6.0 yearsPosted 16.6 years ago

Interventions

Tamoxifendrug

Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks